Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY15.49 CNY
Change Today -0.07 / -0.45%
Volume 14.5M
600267 On Other Exchanges
Symbol
Exchange
Shanghai
As of 3:05 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

zhejiang hisun pharmaceuti-a (600267) Snapshot

Open
CNY15.40
Previous Close
CNY15.56
Day High
CNY15.73
Day Low
CNY15.28
52 Week High
06/15/15 - CNY27.93
52 Week Low
07/8/15 - CNY11.39
Market Cap
15.0B
Average Volume 10 Days
19.4M
EPS TTM
CNY0.27
Shares Outstanding
965.5M
EX-Date
06/18/15
P/E TM
56.7x
Dividend
CNY0.11
Dividend Yield
0.71%
Current Stock Chart for ZHEJIANG HISUN PHARMACEUTI-A (600267)

Related News

No related news articles were found.

zhejiang hisun pharmaceuti-a (600267) Related Businessweek News

No Related Businessweek News Found

zhejiang hisun pharmaceuti-a (600267) Details

Zhejiang Hisun Pharmaceutical Co. Ltd. manufactures and distributes pharmaceuticals. The company’s products include antineoplastic, cardiovascular, anti-infection, endocrine control, anti-parasite, and anti-infective drugs, as well as animal remedies. The company distributes its products under the HISUN brand in approximately 70 countries and regions. The company was founded in 1956 and is headquartered in Taizhou, China.

Founded in 1956

zhejiang hisun pharmaceuti-a (600267) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zhejiang hisun pharmaceuti-a (600267) Key Developments

Zhejiang Hisun Pharmaceutical Co., Ltd. Provides Earnings Guidance for First Half of 2015

Zhejiang Hisun Pharmaceutical Co., Ltd. provided earnings guidance for first half of 2015. The company predicts a year-on-year decrease of between 60% to 80% in its net profit belonging to shareholders of the listed company in the 1st half of 2015.

Zhejiang Hisun Pharmaceutical and Sanofi Enter Agreement on Diabetes Drug Development

Zhejiang Hisun Pharmaceutical has signed an agreement with Sanofi to explore potential cooperation in diabetes treatment. Under the agreement, the two companies may set up a joint venture in mainland China for manufacturing insulin, insulin analogues as well as develop and commercialise other diabetes therapies.

Zhejiang Hisun Pharmaceutical Co., Ltd.(SHSE:600267) dropped from CSI 300 Index

Zhejiang Hisun Pharmaceutical Co., Ltd. will be removed from CSI 300.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600267:CH CNY15.49 CNY -0.07

600267 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600267.
View Industry Companies
 

Industry Analysis

600267

Industry Average

Valuation 600267 Industry Range
Price/Earnings 52.1x
Price/Sales 0.8x
Price/Book 1.1x
Price/Cash Flow 63.2x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZHEJIANG HISUN PHARMACEUTI-A, please visit www.hisunpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.